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(10.7%) had >90% reduction in tumour size. 6 of the 11 with cPR
were HER2 positive, 3 triple negative and 2 luminal type (ER+ve,
PR+ve, HER2–ve).
71.4% of ERBB2 tumours (ER–ve HER2+ve), all with trast-
uzumab included in their chemotherapy regimen, had cPR. This
molecular subtype was significantly more likely to achieve cPR
than luminal subtype (p < 0.05). Oestrogen negative tumours
were more likely to respond then oestrogen positive tumours
(p < 0.05).
Conclusions: This study suggests that Her 2positive, ER–ve high
grade ductal tumours are the most chemosensitive. The results
support the use of trastuzumab in the neo-adjuvant setting. Data
collection is ongoing.
doi:10.1016/j.ejcsup.2010.06.029
O-29 CAN ER/PR AND HER2 RECEPTOR STATUS PREDICT COM-
PLETE PATHOLOGICAL RESPONSE AFTER NEO-ADJUVANT CHE-
MOTHERAPY IN PATIENTS WITH BREAST CANCER?
T. Sircar, R. Athwal, H. Brown, D. Dea, F. Hoar. Birmingham City
Hospital, Birmingham, UK
Aim: The complete pathological response (CPR) rate of the
breast following neo-adjuvant chemotherapy (NAC) in patients
with breast cancer varies from 13% to 29%. The aim of this study
was to establish the incidence of CPR in our unit and investigate if
CPR could be predicted using oestrogen receptor (ER), progester-
one receptor (PR) and human epidermal growth factor receptor
2 (HER2) status.
Method: Patients with breast cancer diagnosed between Janu-
ary 2006 and October 2009 who had NAC followed by surgery were
included in the study.
Results: (See Table 1) Altogether 38 patients had NAC followed
by surgery. Mean clinical size of the tumour was 72 mm. The
commonest chemotherapy regime was Epirubicin-CMF. 8/10
HER2 positive patients received neo-adjuvant trastuzumab. Over-
all 18% (7/38) of patients achieved CPR of the breast and 16% (6/38)
achieved CPR of breast and axilla. The rate of CPR of the breast
was highest in triple negative patients (36%) and ER negative
patients (32%). Post NAC axillary nodes were negative in 45% of
patients (n = 17).
Conclusions: Complete pathological response of the breast was
seen in 18% of patients. ER, PR and HER2 receptor expression
appears to be relevant when predicting CPR, with triple negative
tumours having the highest chance of CPR (36%).
doi:10.1016/j.ejcsup.2010.06.030
O-30 BASAL-LIKE PHENOTYPE IS A PROGNOSTIC MARKER OF
LOCALLY ADVANCED BREAST CANCER BUT NOT A PREDICTIVE
MARKER OF RESPONSE TO NEOADJUVANT ANTHRACYCLINE
CHEMOTHERAPY
M. Shehata, A. Mukherjee, P. Moseley, E. Rakha, I. Ellis, S. Chan.
Nottingham University Hospitals, Nottingham, UK
The basal-like breast cancer is associated with aggressive
behaviour and poor prognosis. In this study we examined the
impact of two different definitions of basal phenotype (BP) on
its prognostic significance in locally advanced primary breast
cancer (LAPC) treated by neoadjuvant anthracycline combination
chemotherapy.
Method: This study included 120 patients diagnosed with LAPC
from 1999 to 2007 at Nottingham University Hospital. IHC was
used for evaluation of a number of markers including ER, PR,
HER2, EGFR, and CK5/6, and CK14. BP was defined in 2 ways as
either any positive expression of CK5/6 and/or CK14 or double
negative expression for ER and HER2 plus positive expression
for CK5/6 and/or EGFR. BP and triple negative (TN) status were
correlated with pCR, PFS and OS.
Result: BP was positive in 46.3% and 24.8% of the cases accord-
ing to the 1st and 2nd definitions. Twenty-nine percent of the
patients were TN. Median follow-up was 62 months. Both defini-
tion did not correlate with pCR to chemotherapy while TN corre-
lated with pCR (p = 0.004). RFS and OS were not significantly
different when the 1st definition of BP was used but were signif-
icant with the 2nd definition (p = 0.016 and <0.001). TN patients
had poor RFS and OS but it was only significant for OS (p = 0.007).
Conclusion: BP in this patient population is an important prog-
nostic but not predictive marker of pCR to anthracycline neoadju-
vant chemotherapy.
The predictive and prognostic value of TN and BP are different,
further studies to clarify the clinical utilities in LAPC are
necessary.
doi:10.1016/j.ejcsup.2010.06.031
Table 1
ER+ ER– HER2+ HER2– ER+HER2+ ER+HER2– ER– PR-HER2+ ER–PR–HER2–(triple–)
Total (n = 38) Total (n = 38) Total (n = 38)
Number and % of patients 19 (50%) 19(50%) 10 (26%) 28 (74%) 5 (13%) 14 (37%) 5 (13%) 14 (37%)
Rate of CPR 5% 32% 10% 21% 0 7% 20% 36%
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